Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D3MG8W
|
|||
Drug Name |
PLN-74809
|
|||
Synonyms |
Bexotegrast; PLN-74809; 2376257-44-0; QCV154PFT4; Pln 74809; Bexotegras; (2S)-4-(2-Methoxyethyl-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid; (2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid; Bexotegras [INN]; Butanoic acid, 4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(4-quinazolinylamino)-, (2S)-; Butanoic acid, 4-[(2-methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(4-quinazolinylamino)-, (2S)-; bexotegrast [INN]; UNII-QCV154PFT4; CHEMBL5095257; SCHEMBL21329445; GTPL12108; US10793564, Compound 5; BDBM465216; GLXC-26826; (S)-4-((2-Methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid; PLN 74809 [WHO-DD]; PLN74809; US10793564, Compound 55; BDBM50594476; AKOS040757614; MS-29155; HY-137561; CS-0140405; (S)-4-[(2-Methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(quinazolin-4-yl)amino]butanoic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecule
|
|||
Indication | Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Phase 2 | [1] | |
Primary sclerosing cholangitis [ICD-11: DB96.2; ICD-10: K83.0] | Phase 2 | [2] | ||
Company |
Pliant Therapeutics
|
|||
Structure |
Download2D MOL |
|||
Formula |
C27H36N6O3
|
|||
Canonical SMILES |
COCCN(CCCCC1=NC2=C(CCCN2)C=C1)CCC(C(=O)O)NC3=NC=NC4=CC=CC=C43
|
|||
InChI |
InChI=1S/C27H36N6O3/c1-36-18-17-33(15-5-4-8-21-12-11-20-7-6-14-28-25(20)31-21)16-13-24(27(34)35)32-26-22-9-2-3-10-23(22)29-19-30-26/h2-3,9-12,19,24H,4-8,13-18H2,1H3,(H,28,31)(H,34,35)(H,29,30,32)/t24-/m0/s1
|
|||
InChIKey |
CWOFQJBATWQSHL-DEOSSOPVSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Integrin alpha-5/beta-1 (ITGA5/B1) | Target Info | Inhibitor | [3] |
Integrin alpha-V/beta-6 (ITGAV/B6) | Target Info | Inhibitor | [3] |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT05621252) A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Evaluation of PLN-74809 on Type 1 Collagen Deposition Using 68Ga-CBP8 PET/MRI Imaging in Participants With Idiopathic Pulmonary Fibrosis (IPF). U.S.National Institutes of Health. | |||
REF 2 | ClinicalTrials.gov (NCT04480840) A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC). U.S.National Institutes of Health. | |||
REF 3 | Dual inhibition of alpha(v)beta(6) and alpha(v)beta(1) reduces fibrogenesis in lung tissue explants from patients with IPF. Respir Res. 2021 Oct 19;22(1):265. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.